Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00760435 · ClinicalTrials.gov registry record · Phase 3
Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease
A Phase 3 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 3
- Development phase
- 196
- Enrollment target
NCT00760435 is a Phase 3 study that has completed, run by University of California, San Diego. The registered enrollment target is 196 participants.
The verdict
NCT00760435, a Phase 3 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 196 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the addition of infliximab to standard primary therapy of intravenous immunoglobulin (IVIG) and high dose aspirin will reduce resistance to therapy in acute Kawasaki disease (KD).
Interventions
- DRUG Placebo
- DRUG Infliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2009-03 |
| Est. Completion | 2012-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00760435
The ClinicalTrials.gov registry entry for NCT00760435 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00760435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00760435 about?
NCT00760435 is a clinical study titled "Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease". The purpose of this study is to determine whether the addition of infliximab to standard primary therapy of intravenous immunoglobulin (IVIG) and high dose aspirin will reduce resistance to therapy in acute Kawasaki disease (KD).
What is the current status of trial NCT00760435?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 196 participants. The study started on 2009-03. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00760435?
The interventions under investigation include: Placebo (DRUG), Infliximab (DRUG).
Who is sponsoring clinical trial NCT00760435?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.